SCHEMBL3661395

SCHEMBL3661395

CCNS(=O)(=O)C(C)(C)C(=O)Nc1nc(C(C)(C)C)cs1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.49
ALDH1A1 P00352 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HPGD P15428 2/20 0.48
KMT2A Q03164 7/20 0.48
NPC1 O15118 7/20 0.48
RAB9A P51151 7/20 0.48
MEN1 O00255 5/20 0.48
MAPK1 P28482 3/20 0.48
POLB P06746 2/20 0.48
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48
TAS1R2 Q8TE23 1/20 0.48
LMNA P02545 5/20 0.47
MAPT P10636 2/20 0.47
RECQL P46063 1/20 0.47
NPSR1 Q6W5P4 3/20 0.47
HSD17B10 Q99714 2/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652189 0.88 ATAD2 (0.45) ATAD2ALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL3658762 0.85 KMT2A (0.44) ATAD2ALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL1619480 0.82 ATAD2 (0.55) ATAD2ALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL1621015 0.82 ATAD2 (0.49) ATAD2ALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL13062829 0.81 L3MBTL1 (0.41) ALDH1A1SMN1; SMN2HPGDKMT2ANPC1
SCHEMBL1621451 0.81 ATAD2 (0.53) ATAD2ALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL1621496 0.80 NPC1 (0.47) ATAD2ALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL766882 0.80 KMT2A (0.49) ATAD2ALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL1621065 0.79 NPC1 (0.53) ATAD2ALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL1621453 0.79 ATAD2 (0.48) ATAD2ALDH1A1SMN1; SMN2HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US claimed
EP-2217565-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-05-22 EP claimed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US claimed
EP-2217565-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2010-08-18 EP claimed
WO-2009061652-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-14 WO claimed
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US disclosed
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US disclosed
EP-2217565-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-05-22 EP disclosed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US disclosed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US disclosed
WO-2009061652-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 ATAD2 3872/4885ALDH1A1 1785/4885SMN1; SMN2 4442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.